Verona Pharma
plc
(“Verona Pharma” or the
“Company”)
Director
Dealings
17 June 2015, Cardiff –
Verona Pharma plc (AIM: VRP) today received notification that on
17 June 2015 David Ebsworth, Director
of the Company, purchased 250,000 ordinary shares of 0.1 pence each of the Company (“Ordinary Shares”)
at a price of 4.7 pence per Ordinary
Share.
Following the transaction David
Ebsworth has a total interest of 3,829,774 Ordinary Shares,
representing 0.38% of the total voting rights.
-Ends-
For further information please
contact:
Verona Pharma plc
Tel: +44 (0) 20 3283
4200
Jan-Anders Karlsson, CEO
N+1 Singer
Tel: +44 (0)20
7496 3000
Aubrey Powell / Jen Boorer
FTI Consulting
Tel: +44 (0)20 3727
1000
Julia Phillips / Simon
Conway
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as COPD, asthma and cystic fibrosis. Verona
Pharma's lead drug, RPL554, is a first-in-class drug currently in
Phase II trials as a nebulised treatment for acute exacerbations of
COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has
both bronchodilator and anti-inflammatory effects, which are
essential to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader franchise around RPL554 to
maximise its value, both to patients and to investors. This
includes the very significant markets for COPD and asthma
maintenance therapy. The Company is also exploring the potential of
the drug in different diseases, such as cystic fibrosis, where it
is in pre-clinical testing.